TMS for Anxiety: How Transcranial Magnetic Stimulation Targets GAD, Social Anxiety, and OCD-Spectrum Disorders

At a Glance

Anxiety disorders are the most prevalent mental health conditions globally, affecting approximately 18% of adults. While first-line treatments — cognitive-behavioural therapy (CBT) and SSRIs — work well for many patients, a substantial subgroup with treatment-resistant generalized anxiety disorder (GAD), social anxiety, or OCD-spectrum presentations remains inadequately treated. Transcranial magnetic stimulation is increasingly positioned as a viable alternative or augmentation strategy for this population. Unlike TMS for depression, where left dorsolateral prefrontal cortex (DLPFC) stimulation is the established protocol, anxiety TMS targets partially distinct circuits, particularly the dorsomedial prefrontal cortex (DMPFC) and its connections with the amygdala, anterior cingulate cortex (ACC), and insula.

For patients who have not responded to TMS, IV ketamine infusion therapy offers a complementary rapid-acting mechanism targeting glutamate receptors rather than cortical excitability.

The Neuroscience of Anxiety: Why TMS Targets Different Circuits

The anxiety network is not the same as the depression network, though the two overlap considerably. Core features of pathological anxiety include:

• Hyperactive amygdala responses to threat-related stimuli
• Deficient prefrontal regulation of amygdala reactivity — particularly from the medial and ventromedial prefrontal cortex (vmPFC)
• Overactive anterior insula contributing to interoceptive threat appraisal
• Reduced ACC activation impairing fear extinction and cognitive flexibility

Neuroimaging studies consistently show that patients with GAD exhibit reduced functional connectivity between the mPFC and amygdala at rest, alongside elevated resting-state activity in the right DLPFC. This provides the neurological rationale for TMS protocols that either:

1. Excite the mPFC/DMPFC using high-frequency (10 Hz) rTMS to strengthen top-down inhibition of the amygdala
2. Inhibit the right DLPFC using low-frequency (1 Hz) rTMS to reduce the asymmetric hyperactivation thought to drive anxious rumination

The FDA-cleared BrainsWay H7 deep TMS coil was specifically engineered to reach the DMPFC at depth, enabling stimulation of the cingulate and its connections that a standard figure-8 coil cannot reliably access. This anatomical reach is a key reason dTMS has accumulated the strongest evidence base specifically for OCD.

TMS Protocols by Anxiety Disorder

Generalized Anxiety Disorder (GAD)

Most published GAD trials use one of three approaches:

High-frequency rTMS to the right DLPFC (excitatory): A 2019 randomized controlled trial (Zwanzger et al., European Neuropsychopharmacology) found significantly greater reductions on the Hamilton Anxiety Rating Scale (HAM-A) versus sham after 10 Hz stimulation of the right DLPFC. The rationale is that right frontal hypoactivation in GAD — paradoxically — accompanies the emotional overactivation, and boosting it normalises hemispheric balance.

Low-frequency rTMS to the right DLPFC (inhibitory): A 1 Hz protocol over the right DLPFC mimics the theoretical model of right-frontal overactivity in anxiety. Some open-label series report robust HAM-A reductions of 40–50% from baseline, though placebo-controlled data are more limited.

DMPFC stimulation via H7 coil: Used in anxious-depression cohorts, this approach has shown reductions in both mood and anxiety scores. It is increasingly used off-label for GAD when coil availability allows.

Typical GAD response is clinically meaningful — a HAM-A reduction of ≥50% — in approximately 50–65% of patients in open-label settings, with placebo-controlled estimates somewhat lower.

OCD and OCD-Spectrum

This is the best-evidenced anxiety-related indication for TMS. The FDA cleared the BrainsWay H7 deep TMS system for OCD in 2018, based on a multisite RCT demonstrating significantly greater response versus sham (38% vs 11% response at 6 weeks). The key features:

• Protocol: 20 Hz dTMS to the DMPFC, 20 sessions over 4 weeks
• Sessions include a brief symptom provocation step (30 seconds of exposure to a standardized OCD-relevant image or script) immediately before stimulation — this “primes” the circuit
• Response rate (~38%) is lower than depression TMS response, but the unmet need in OCD is severe, and TMS is well tolerated even in patients already on high-dose SSRIs plus augmentation

Social Anxiety Disorder (SAD)

Social anxiety has received less focused TMS research than GAD or OCD, but the evidence that exists is encouraging. A landmark study by Prasko et al. found that excitatory rTMS to the left DLPFC reduced SAD symptoms on the Liebowitz Social Anxiety Scale compared to sham. Inhibitory right DLPFC protocols are also under evaluation based on the hyperactivation-of-right-frontal-circuits hypothesis.

PTSD

PTSD involving hyperarousal, intrusions, and avoidance overlaps mechanistically with anxiety. Several RCTs using right DLPFC rTMS have shown significant reductions in PTSD Checklist (PCL-5) scores and Clinician-Administered PTSD Scale (CAPS) ratings. A 2020 meta-analysis (Karsen et al., Journal of Psychiatric Research) including seven RCTs reported a pooled effect size of Cohen’s d = 0.69 for rTMS in PTSD — a moderate-to-large effect.

Comparing TMS for Anxiety vs. TMS for Depression

In clinical practice, anxiety and depression frequently co-occur. When GAD or social anxiety is the primary complaint but significant depressive features are present, the standard left DLPFC protocol often improves anxiety secondarily. When anxiety is the primary, dominant condition without significant depression, DMPFC dTMS or right DLPFC rTMS may be preferred.

What Patients Experience: Session-by-Session Expectations

Weeks 1–2

Most patients notice little subjective change, though some report reduced nighttime rumination. Mild scalp tingling or superficial headache after sessions is common and resolves within hours.

Weeks 3–4

The majority of eventual responders begin to notice reduced worry frequency, improved sleep quality, and less physical tension. Partners and family members sometimes report changes before the patient themselves.

Weeks 5–6 and Maintenance

Response typically consolidates by the end of the acute course. A subset of patients undergoes maintenance sessions (weekly or biweekly) to sustain benefit. A 2021 follow-up analysis of OCD dTMS patients found that two-thirds of acute responders maintained response at 1-year follow-up with periodic maintenance.

Combining TMS with Psychotherapy and Pharmacotherapy

TMS does not replace CBT; the two approaches are complementary and in some protocols synergistic. The rationale:

• Neuroplasticity priming: TMS-induced increases in BDNF and synaptic plasticity create a window of enhanced learning. Delivering exposure-based CBT (or OCD provocation exercises) during or immediately after TMS may amplify therapeutic gain.
• Medication augmentation: Patients on stable SSRI or SNRI doses can continue medication during TMS. There is no evidence of adverse interactions, and several studies suggest additive effects.
• Anxiolytic taper facilitation: Some clinicians use TMS as a bridge while tapering benzodiazepines in chronically dependent patients, providing symptom stabilisation during the taper.

Safety Considerations and Contraindications

TMS for anxiety carries the same contraindication profile as TMS for depression:

• Absolute: Metallic implants in or near the skull (cochlear implants, deep brain stimulators, aneurysm clips), active seizure disorder
• Relative: Pregnancy (limited data; generally deferred), severe migraines (may exacerbate temporarily), active substance use disorder
• Seizure risk: Approximately 1 in 10,000–30,000 sessions; risk is higher with high-frequency protocols and is mitigated by adherence to published dosing guidelines

Anxiety patients specifically: TMS occasionally produces transient heightened anxiety in the first 1–3 sessions as the circuit is activated. This is expected and does not predict lack of benefit — it typically resolves as the course progresses. Clinicians should inform patients of this phenomenon to prevent early dropout.

Related Articles

• TMS Therapy: Complete Clinical Guide — foundational overview of TMS technology, coil types, and general indications
• TMS for Depression: Evidence and Protocols — the established left DLPFC approach compared with anxiety protocols
• Neurofeedback vs Biofeedback: Which for Anxiety? — non-invasive self-regulation alternatives
• Vagus Nerve Stimulation and Inflammation — parasympathetic approaches that complement TMS
• Selank Dosage and Anxiety Management — pharmacological peptide options for treatment-resistant anxiety

References

1. Zwanzger P, et al. (2019). Repetitive transcranial magnetic stimulation in generalized anxiety disorder. European Neuropsychopharmacology, 29(3), 379–388.
2. Carmi L, et al. (2019). Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry, 176(11), 931–938. PMID: 31109199
3. Karsen EF, et al. (2014). Review of the effectiveness of transcranial magnetic stimulation for post-traumatic stress disorder. Brain Stimulation, 7(2), 151–157. PMID: 24461572
4. Prasko J, et al. (2006). The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuroendocrinology Letters, 27(3), 327–332. PMID: 16816823
5. Trevizol AP, et al. (2016). Transcranial magnetic stimulation for posttraumatic stress disorder. Clinical Neurophysiology, 127(8), 2649–2657. PMID: 27289411
6. Huang YZ, et al. (2005). Theta burst stimulation of the human motor cortex. Neuron, 45(2), 201–206. PMID: 15664172
7. Philip NS, et al. (2019). Transcranial Magnetic Stimulation as a Treatment for Post-Traumatic Stress Disorder. Journal of ECT, 35(4), 237–243. PMID: 31688247